Literature DB >> 12017289

Sensitivity of nucleotide excision repair-deficient human cells to ionizing radiation and cyclophosphamide.

D Murray1, Loretta Vallee-Lucic, Elizabeth Rosenberg, Borje Andersson.   

Abstract

Nucleotide excision repair (NER)-deficient rodent and human cells (such as those derived from patients with xeroderma pigmentosum, XP) are hypersensitive to UV light. Some of these cell lines, specifically certain rodent mutants with severe defects in the ERCC1 and XPF genes, are dramatically sensitive to crosslinking agents such as phosphoramide mustard (PM). These crosslink-sensitive rodent mutants also exhibit sensitization to gamma-rays under hypoxic (but not under aerated) conditions. Like their rodent counterparts, human XP cells are highly sensitive to UV light; however, none of the human XP lines, even XPF, displays extreme hypersensitivity to crosslinking agents. Studying XP cells, therefore, allows us to further assess the extent to which the phenotypic characteristic of hypoxia-specific radiosensitization of mammalian cells tracks with defects in crosslink repair (as opposed to NER). The sensitivity to PM and gamma-rays of normal human fibroblasts and human XP fibroblasts from two complementation groups, XPA and XPF, was assessed using a clonogenic survival assay. Compared with normal cells, XPA cells were not appreciably hypersensitive to PM or to gamma-rays under either aerated or hypoxic conditions. XPF cells were modestly (approximately 1.75-fold) sensitive to PM but showed no significant radiosensitization under either aerated or hypoxic conditions. Thus, although the phenotype of human XPF cells is quite different from that of "severe" rodent XPF mutants such as UV41, the characteristic of hypoxia-specific radiosensitization consistently tracks with extreme hypersensitivity to crosslinking agents and is separable from UV sensitivity (and thus from defects in NER).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12017289

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Reduced hematopoietic reserves in DNA interstrand crosslink repair-deficient Ercc1-/- mice.

Authors:  Joanna M Prasher; Astrid S Lalai; Claudia Heijmans-Antonissen; Robert E Ploemacher; Jan H J Hoeijmakers; Ivo P Touw; Laura J Niedernhofer
Journal:  EMBO J       Date:  2005-02-03       Impact factor: 11.598

2.  ERCC1-XPF endonuclease facilitates DNA double-strand break repair.

Authors:  Anwaar Ahmad; Andria Rasile Robinson; Anette Duensing; Ellen van Drunen; H Berna Beverloo; David B Weisberg; Paul Hasty; Jan H J Hoeijmakers; Laura J Niedernhofer
Journal:  Mol Cell Biol       Date:  2008-06-09       Impact factor: 4.272

3.  The prognostic value of excision repair cross-complementation group 1 (ERCC1) in patients with small cell lung cancer (SCLC) receiving platinum-based chemotherapy: evidence from meta-analysis.

Authors:  Yanlong Yang; Xiuping Luo; Nuo Yang; Ronghao Feng; Lei Xian
Journal:  PLoS One       Date:  2014-11-06       Impact factor: 3.240

4.  Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells.

Authors:  Benigno C Valdez; Yang Li; David Murray; Yan Liu; Yago Nieto; Richard E Champlin; Borje S Andersson
Journal:  Oncotarget       Date:  2017-12-17

5.  High/positive expression of ERCC1 predicts poor treatment response and survival prognosis in nasopharyngeal carcinoma: A systematic meta-analysis from 21 studies.

Authors:  Lin Yang; Wenjie Wei; Lei Zhou; Jing Wang; Guangyuan Hu
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.